Loading
Imatinib shrank tumours in about a third of patients with melanoma carrying KIT mutations, but only in those with mutations in specific exons, defining a small targetable subgroup among mucosal and acral melanomas.
Phase 2 study of 25 patients with advanced melanoma with KIT mutations or amplification arising on mucosal, acral or chronically sun-damaged skin treated with imatinib.
Overall response was 29 percent, with durable responses confined to tumours with KIT mutations in exons 11 and 13 (particularly L576P and K642E), and none in tumours with KIT amplification alone; median time to progression was 3.7 months overall.
KIT testing is worthwhile in mucosal and acral melanoma, and imatinib is a guideline option for exon 11 or 13 mutations after or alongside immunotherapy.
Shares Acral melanoma, Mucosal melanoma, Journal of Clinical Oncology.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Imatinib, Journal of Clinical Oncology.
Shares Acral melanoma, Mucosal melanoma.
Shares Acral melanoma, Mucosal melanoma.
Shares Imatinib, Journal of Clinical Oncology.